Last Updated: 23 September 2026
OXB plc — legally still Oxford Biomedica plc — is a contract development and manufacturing organisation (CDMO) for cell and gene therapies. It makes the viral vectors, principally lentiviral and adeno-associated virus (AAV) vectors, that biotech and pharma clients use to deliver genetic material into patients' cells, and it earns fees for developing processes and manufacturing batches under contract. 2026 has been a year of sharp swings: the board rejected four take-private proposals from EQT in January and February, then on 7 August cut full-year revenue guidance to £180–200m from £220–240m. This report sets out the figures from the company's own results announcements, with no analyst opinions and no price targets.
1. Company Snapshot
| Field | Value |
|---|---|
| Legal name | Oxford Biomedica plc, trading as OXB since September 2024 |
| Exchange / ticker | London Stock Exchange Main Market, OXB (OXB.L) |
| Sector | Healthcare — cell and gene therapy CDMO (viral vector development and manufacturing) |
| Sites | Oxfordshire, UK; Lyon and Strasbourg, France; Bedford, Massachusetts and Durham, North Carolina, US |
| CEO / Leadership | Dr Frank Mathias, Chief Executive Officer. CFO Dr Lucinda Crabtree; Chair Dr Roch Doliveux; COO Eric Schmidhäuser (joined August 2026) |
| Employees | 1,017 at 30 June 2026 (986 at 31 December 2025) |
| Revenue (FY2025) | £168.7m, up 31% reported |
| Net income (FY2025) | Loss after tax £30.6m; basic EPS (26.92)p |
| Shares in issue | 121,049,785 at 31 August 2026, none in treasury |
| Client book | 50 clients and 59 programmes as at September 2026, including 3 commercial agreements |
| Reporting currency / year end | Pounds sterling; 31 December. Half-yearly results with trading updates |
OXB earns most of its revenue in US dollars from US clients but reports in sterling, so the constant-currency figures it quotes alongside reported numbers differ slightly. The company pays no dividend.
2. Bull Case and Bear Case
Bull Case
- Revenue is growing again: revenue rose 31% to £168.7m in FY2025 and a further 9% to £79.8m in H1 2026. About £168m of the guided FY2026 revenue was covered by contracts as at September 2026.
- A broadening client base: OXB added 17 new clients in H1 2026 and 4 more after the period end, taking the book to 50 clients and 59 programmes, up from 40 clients and 48 programmes in March 2026. Its non-risk-adjusted pipeline is about $713m, up roughly 30% year on year.
- Multi-site, multi-vector capacity now in place: Durham's GMP facility is online with its first GMP run complete, the French AAV and lentiviral suites are GMP-qualified, and Oxfordshire's capacity expansion was completed in H1 2026. The company offers both lentiviral and AAV work on two continents.
- Management's stated medium-term trajectory: revenue growth of 25–30% in both FY2027 and FY2028, at least double-digit EBITDA margin in FY2027, and an ambition of about £500m of revenue in 2030.
- Strategic value was tested by a bidder: EQT made four take-private proposals in January and February 2026, all rejected by the board as undervaluing the company, before walking away on 25 February.
Bear Case
- Guidance has already been cut once: on 7 August 2026 FY2026 revenue guidance fell from £220–240m to £180–200m, and the EBITDA margin target dropped from about 10% to mid-single digits excluding one-offs, citing client deferrals, staged ordering and a six-month delay at Durham.
- Heavy client concentration: the two largest clients provided about 71% of H1 2026 revenue (£42.0m and £14.2m), up from about 62% in FY2025. A single client's procurement change was one of the reasons for the guidance cut.
- Still loss-making and burning cash: the H1 2026 loss after tax was £37.0m and net cash used in operating activities was £17.4m. Cash fell from £96.9m at the year end to £66.8m at 31 August 2026.
- Short sellers are building positions: the FCA aggregated net short position rose from 2.02% on 9 July to 7.67% on 21 September 2026.
3. Revenue Segments
OXB reports revenue by type of service. The FY2025 split is below; in H1 2026 manufacturing rose to 54% of revenue, development was 34%, procurement 10.6% and licences 1.5%.
| Segment | % of revenue | What it is |
|---|---|---|
| Manufacturing — £81.1m | 48.1% | GMP production of viral vector batches for clinical trials and commercial supply, including commercial lentiviral vector supply under a multi-year agreement with BMS signed in February 2026 |
| Development — £60.1m | 35.6% | Process and analytical development work that takes a client's vector from research towards a manufacturable, regulator-ready process |
| Procurement and storage — £22.3m | 13.2% | Raw materials procured and recharged to clients, plus storage of client material |
| Licences, milestones and royalties — £5.2m | 3.1% | Income from licensing OXB's vector technology and intellectual property to partners |
By client location in FY2025, the US accounted for 83.9% of revenue (£141.6m), Europe 14.2%, the UK 1.8% and the rest of the world 0.1%.
4. Business Model & Moat
How it makes money. OXB is a service business. Clients pay for development work, for manufacturing runs, and for materials procured on their behalf. Revenue is recognised as work progresses, so it rises and falls with clients' clinical timetables. Early-stage programmes bring development fees; programmes that reach late-stage trials and commercial approval bring recurring manufacturing revenue. Of the 59 programmes in the book in September 2026, 50 were pre-clinical to early clinical, 6 late-stage clinical and 3 commercial.
What protects it. Viral vector manufacturing is technically demanding and heavily regulated. OXB's platforms include LentiVector and the TetraVecta fourth-generation lentiviral system, the inAAVate dual-plasmid AAV platform and stable producer cell lines, plus an FDA-approved commercial-scale site in Durham. Once a client has run a trial on vector from a particular process and site, switching manufacturer means re-validating, which creates stickiness for programmes that progress.
Operating leverage cuts both ways. The cost base — people, cleanrooms and leases — is largely fixed. Gross margin fell to 37% in H1 2026 from 43% a year earlier as new capacity in Durham and France carried costs ahead of revenue. Management targets an EBITDA margin approaching 30% by FY2030/31 if utilisation rises as planned.
Where the model is weakest. Revenue depends on a small number of large clients and on biotech funding conditions that determine whether clinical programmes proceed. The August 2026 guidance cut showed how quickly deferrals translate into lower revenue.
5. Financial Health
All figures below come from OXB's own preliminary and interim results announcements. Revenue is in pounds sterling; EPS in pence.
| Fiscal Year | Revenue (£m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | 142.8 | +62.8% | 22.77p | 22.77p† | Nil | Nil |
| FY2022 | 140.0 | -2.0% | (41.29)p | (41.29)p† | Nil | £39.8m |
| FY2023 | 89.5 | -36.1% | (163.11)p | (163.11)p† | Nil | £38.5m |
| FY2024 | 128.8 | +43.9% | (41.75)p | (41.75)p† | Nil | £39.8m |
| FY2025 | 168.7 | +31.0% | (26.92)p | (26.92)p† | Nil | £41.5m |
† OXB does not report adjusted EPS; the Adjusted EPS column repeats basic IFRS EPS. The FY2021 YoY figure is against FY2020 revenue of £87.7m; FY2021 revenue was lifted by manufacturing of the Oxford/AstraZeneca COVID-19 vaccine. Long-term debt is non-current loans (the Oaktree facility) and excludes lease liabilities, which were £100.6m non-current at 31 December 2025.
OXB reports half-yearly. The table below runs most recent period first, with the FY2025 total in bold.
| Quarter / Half | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| H1 2026 (to 30 Jun 2026) | £79.8m | (30.39)p† | (30.39)p |
| H2 2025 (derived)‡ | £95.5m | ~(1.57)p† | ~(1.57)p |
| H1 2025 (to 30 Jun 2025) | £73.2m | (25.35)p† | (25.35)p |
| H2 2024 (derived)‡ | £78.0m | ~(10.87)p† | ~(10.87)p |
| FY2025 total | £168.7m | (26.92)p† | (26.92)p |
† No adjusted EPS is reported; basic EPS is repeated. ‡ Second-half figures are derived by subtracting the reported first half from the full year. Derived EPS is approximate because the share count rose after the August 2025 placing.
Profitability. FY2025 operating EBITDA, on OXB's own definition, was £2.3m reported (£8.1m at constant currency), including a one-off £9.9m gain on the Durham acquisition; the operating loss was £22.5m. In H1 2026 operating EBITDA was a loss of £7.8m (adjusted £(2.5)m, excluding Durham pre-revenue and integration costs, Bedford redundancies and one-offs) and the operating loss widened to £29.1m, including a £7.6m impairment of French property, plant and equipment.
Cash flow, FY2025. Net cash generated from operating activities was £0.5m after a £5.1m R&D tax credit receipt. Purchases of property, plant and equipment were £4.8m, so free cash flow was about negative £4.3m. Depreciation was £17.6m and amortisation £2.3m, a combined £19.8m. Lease payments were a further £12.4m, and the August 2025 placing at 431p raised £58.1m net.
Cash flow, H1 2026. Net cash used in operating activities was £17.4m and capex £6.9m. OXB's own net cash outflow measure, which also includes interest and leases, was £34.3m.
Balance sheet. Cash was £96.9m at 31 December 2025, £75.3m at 30 June 2026 and £66.8m at 31 August 2026. Non-current loans under the Oaktree facility were £53.8m at 30 June 2026 ($75m drawn of a facility of up to $125m maturing August 2029), with no current borrowings. Lease liabilities totalled £104.8m. Net assets fell to £58.1m from £91.3m. The board states that the group would continue to comply with its Oaktree covenants beyond December 2027 even if all downside scenarios crystallised, and that if base-case cash flows do not materialise it will begin mitigating actions by the end of Q4 2026.
Guidance (reiterated 22 September 2026). FY2026 revenue £180–200m at constant currency; EBITDA margin mid-single-digit % excluding one-off costs and low-single-digit % reported; FY2027 and FY2028 revenue growth of 25–30%; FY2027 EBITDA margin at least double-digit; about £50m of capex across 2026–27, then £20–25m a year.
6. Valuation Metrics
Share prices, and figures worked out from them, are not shown for London-listed companies on ChartsView.
Raw metrics, September 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Short interest (% of float) | 7.67% of issued share capital, FCA aggregated net short position at 21 September 2026, up from 2.02% on 9 July 2026. The FCA reports against issued share capital, not free float |
7. What Are They Building
A four-country manufacturing network. OXB has spent 2025–26 turning a UK lentiviral specialist into a multi-site, multi-vector CDMO. Durham, North Carolina — bought from a Resilience subsidiary for $4.5m in October 2025 — is an FDA-approved commercial-scale site; GMP is now online there and the first GMP run is complete, with commercial AAV manufacturing and fill-finish to follow, about six months later than originally planned. In France, AAV and 200-litre lentiviral suites are GMP-qualified, with the first full-scale GMP runs due in H2 2026. Oxfordshire completed a GMP capacity expansion in H1 2026. Bedford, Massachusetts has been refocused on process and analytical development only.
Platforms. The technology stack includes LentiVector and the TetraVecta fourth-generation lentiviral system, the inAAVate dual-plasmid AAV platform with a multi-serotype purification toolbox, AdenoVate, stable producer and packaging cell lines, and process work for in vivo CAR-T lentiviral vectors. A fast-track offering launched on 13 April 2026 promises AAV to GMP in as little as seven months and lentiviral vectors in as little as nine.
Commercial pipeline. OXB signed a multi-year commercial lentiviral supply agreement with BMS on 4 February 2026, a licensing and option agreement with VVMF in Australia on 18 March, and an AAV process development and GMP agreement with Plowshare Therapies on 16 July, to be run at Durham. The client book stood at 50 clients and 59 programmes in September 2026. The June 2026 Capital Markets Event set out an ambition of about £500m of revenue in 2030 and an EBITDA margin approaching 30% by FY2030/31, with capex of about £50m across 2026–27.
8. Peer Comparison
| Peer | Key 2025 metric |
|---|---|
| OXB (OXB.L) | FY2025 revenue £168.7m, +31%; operating EBITDA £2.3m (company results, 26 Mar 2026) |
| Lonza (LONN.SW) | FY2025 sales CHF 6.5bn, +21.7% at constant exchange rates; CORE EBITDA margin 31.6% (company release, 28 Jan 2026) |
| Samsung Biologics (207940.KS) | FY2025 revenue KRW 4,557bn; operating profit KRW 2.07tn (company release) |
| Fujifilm Holdings (4901.T), parent of Fujifilm Diosynth | Group revenue ¥3,357.0bn for the year to March 2026; biologics CDMO revenue is not separately disclosed in the release reviewed |
| Charles River Laboratories (CRL) | FY2025 revenue $4.02bn, down 0.9% (company release) |
OXB is a fraction of the size of the diversified CDMOs above, each of which spans far more modalities. Its direct viral-vector competitors are mostly private or divisions of larger groups: AGC Biologics is a subsidiary of AGC Inc and Genezen is privately held. That scarcity of listed pure-play vector manufacturers is one reason OXB attracted private-equity interest in early 2026.
9. Insider Activity
CEO Dr Frank Mathias and CFO Dr Lucinda Crabtree received long-term incentive and deferred bonus awards in April 2026; neither has made an open-market purchase or sale in 2026. The market sales below were by other senior managers (PDMRs) on exercising options and vested awards. Figures are from OXB's PDMR dealing RNS announcements; values are derived from shares multiplied by price.
| Name | Date | Type | Shares | Plan Type |
|---|---|---|---|---|
| Lisa Doman (CPO) | 22 May 2026 | Exercise + sale | 3,564 | Deferred bonus plan |
| Natalie Walter (CLO) | 22 May 2026 | Exercise + sale | 3,816 | Deferred bonus plan |
| Kathleen Miller (Head of HR) | 18 May 2026 | Vest + sale | 4,486 vested; 1,578 sold | Restricted stock units |
| Lisa Doman (CPO) | 12 May 2026 | Exercise + sale | 13,300 | Deferred bonus plan and ESOS options |
| Natalie Walter (CLO) | 12 May 2026 | Exercise + sale | 3,057 | SAYE options (exercise price 294.4p) |
| Dr Frank Mathias (CEO) | 07 Apr 2026 | Award | 478,119 LTIP + 71,891 DBP | 2026 LTIP and deferred bonus plan; 2024 and 2025 LTIP awards of 43,790 and 46,195 also reinstated |
| Dr Lucinda Crabtree (CFO) | 07 Apr 2026 | Award | 156,884 LTIP + 47,179 DBP | 2026 LTIP and deferred bonus plan |
Substantial-holder movements have been more significant than director dealings. Vulpes Investment Management cut its holding to 5.78% from 6.56% (RNS 3 September 2026), and Irenic Capital Management disclosed a 5.41% interest on 17 September 2026, of which 5.35% is held through financial instruments rather than shares.
10. Key Risks
- Client concentration (Commercial): the two largest clients provided about 71% of H1 2026 revenue. A change in procurement or approval pathway at one larger client contributed directly to the August 2026 guidance cut.
- Programme deferrals and staged ordering (Commercial): clients deferring programmes or ordering work in smaller stages reduce near-term revenue visibility; OXB names failure to convert opportunities and rapid technological change among its principal risks.
- Execution of the site network (Operational): Durham's GMP readiness slipped by six months and the French operation required a £7.6m impairment in H1 2026. Both the US and French cost centres missed budget.
- Cash burn and covenant headroom (Financial): cash fell from £96.9m to £66.8m between December 2025 and August 2026. The board says covenants remain met in its downside case but has flagged possible investment cuts, site rationalisation and workforce reductions from the end of Q4 2026 if base-case cash flows do not materialise.
- Quality and regulatory (Regulatory): as a GMP manufacturer of material for patients, OXB is exposed to batch failures, inspection findings and product-quality claims; outdated GMP documentation and quality records are listed among its risks.
- Currency (Financial): about 84% of revenue comes from US clients and the Oaktree loan is dollar-denominated, while the company reports in sterling.
11. Recent Developments
- 22 Sep 2026 — H1 2026 interim results. Revenue £79.8m, up 9% (10% at constant currency). Operating EBITDA £(7.8)m; adjusted £(2.5)m. Loss after tax £37.0m, including a £7.6m impairment of French assets. Cash £75.3m at 30 June. FY2026 guidance of £180–200m revenue reiterated; 17 new clients in the half and 4 since.
- 21 Sep 2026 — Short position reaches 7.67%. The FCA's aggregated net short position for OXB rose to 7.67% at 21 September, from 3.71% on 7 August.
- 17 Sep 2026 — Irenic Capital discloses 5.41%. The interest is almost entirely held through financial instruments (5.35%), announced by RNS on 21 September.
- 03 Sep 2026 — Vulpes reduces stake. Vulpes Investment Management's holding fell to 5.78% from 6.56% in July.
- 07 Aug 2026 — Half-year trading update and guidance cut. FY2026 revenue guidance lowered to £180–200m from £220–240m and EBITDA margin guidance to mid-single digits excluding one-offs, citing client programme deferrals, staged ordering, a procurement change at a larger client and a six-month Durham delay.
- 16 Jul 2026 — Plowshare Therapies agreement. AAV process development and GMP manufacturing agreement, to be carried out at Durham.
- 02 Jun 2026 — Capital Markets Event. OXB set an ambition of about £500m of revenue in 2030 and an EBITDA margin approaching 30% by FY2030/31.
- 26 Mar 2026 — FY2025 results. Revenue £168.7m, up 31%; operating EBITDA £2.3m; loss after tax £30.6m; cash £96.9m at 31 December 2025.
- 25 Feb 2026 — EQT walks away. EQT confirmed it would not make an offer after the board rejected four take-private proposals as undervaluing OXB.
For the macro and rate backdrop that drives biotech funding, see the ChartsView Economic Calendar.
12. Key Dates to Watch
- 24 Sep 2026 — management presentation to retail investors on the Investor Meet Company platform, following the interim results
- Expected Q4 2026 — business update per the company's investor calendar; also the point by which the board has said it would start mitigating actions if base-case cash flows do not materialise. No date published
- Expected Feb 2027 — FY2026 trading update, the first read on whether revenue landed within the £180–200m guidance. No date published
- Expected Mar 2027 — FY2026 preliminary results. FY2025 results were published on 26 March 2026; no FY2026 date has been announced
- Expected May 2027 — Annual General Meeting; the 2026 AGM was held on 7 May 2026
- Expected Aug 2029 — maturity of the Oaktree senior secured facility of up to $125m
Discuss this research with other investors in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 2 September 2026
Hims & Hers Health sells prescription and non-prescription treatment on a recurring subscription, across sexual health, hair loss, dermatology, mental health, hormone health, weight loss and, since 2025, at-home diagnostics. It has grown revenue from $271.9m in FY2021 to $2,347.6m in FY2025, and the trailing twelve months to 30 June 2026 reached $2,578.1m. It is also, in 2026, a company being sued by the Federal Trade Commission, investigated by the Securities and Exchange Commission's enforcement division, referred to the Department of Justice, placed under a Visa monitoring programme, and running GAAP losses for the first time in two years while integrating a $1.15bn acquisition. Both halves of that description are true simultaneously, and this report sets out what the filings say about each — without ratings or price targets.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Hims & Hers Health, Inc. |
| Ticker / exchange | HIMS, New York Stock Exchange |
| Sector | Healthcare — consumer telehealth and direct-to-consumer pharmacy |
| Market cap | ~$6.64bn at the close on 1 September 2026 |
| Share price | $28.44 (close, 1 September 2026) |
| Revenue (FY2025) | $2,347.6m, up 59.0% year on year; trailing twelve months to 30 June 2026 $2,578.1m |
| Net income (FY2025) | $128.4m. The trailing twelve months to 30 June 2026 is a net loss of ~$142.0m. |
| GAAP diluted EPS (FY2025) | $0.51 |
| Adjusted EBITDA (FY2025) | $318.0m; trailing twelve months $249.3m |
| Subscribers | 2,891,000 at 30 June 2026, up 19% year on year |
| CEO / Leadership | Andrew Dudum, co-founder and Chief Executive Officer since September 2016; Oluyemi "Yemi" Okupe, Chief Financial Officer; Dr Patrick Carroll, Global Chief Medical Officer |
| Employees | 2,442 as at 31 December 2025 per the FY2025 Form 10-K, up around 49% year on year. This predates the Eucalyptus acquisition completed on 2 June 2026, and no post-acquisition figure has been disclosed. |
| Shares outstanding | 233,297,933 at 30 June 2026 (224,920,310 Class A plus 8,377,623 Class V) |
| Dividend | None. Hims & Hers has never paid a dividend. |
| Fiscal year end | 31 December |
Cross-reference: this report also links to the ChartsView Live Charts tool and the Economic Calendar.
2. The Bull and Bear Case
Bull Case
- Growth re-accelerated hard in the June quarter: revenue rose 38% to $753.2m in Q2 2026 after only 4% growth in Q1 2026, and management raised full-year 2026 revenue guidance from $2.8–3.0bn to $3.1–3.3bn. Subscribers reached 2.891 million, up 19%.
- International is now material and growing from nothing: rest-of-world revenue was $131.4m in Q2 2026 against $7.5m a year earlier, and is 17.4% of group revenue. Management expects at least $600m of international revenue in 2026, with the United Kingdom, Australia and Germany each above a $100m annualised run rate.
- Unit economics are improving even as gross margin falls: monthly revenue per average subscriber rose from $76 to $92, up 21%, while marketing fell from 40.0% to 34.8% of revenue. The company is extracting more from each customer while spending proportionally less to acquire them.
- The Novo Nordisk relationship has been repaired and made commercial: on 9 March 2026 Hims announced access to branded Ozempic and Wegovy injections and tablets, and Novo simultaneously dismissed its patent lawsuit. The single largest overhang from 2025 has been converted into a supply arrangement.
- Vertical integration is real and on the balance sheet: property, equipment and software stood at $364.2m at 30 June 2026, reflecting owned pharmacy and fulfilment capacity, a California peptide manufacturing facility and the Trybe Labs and YourBio diagnostics assets — an unusually heavy asset base for a business often described as pure telehealth.
Bear Case
- The Federal Trade Commission is suing the subscription model itself: the complaint filed on 29 July 2026 attacks health-data sharing with advertising platforms, cancellation flows, and charging customers before they have spoken to a provider. It seeks permanent injunctive relief, monetary relief, disgorgement and civil penalties. The shares fell 14.73% on the day.
- Profitability has reversed: gross margin fell from 76% in Q2 2025 to 64% in Q2 2026 and from 74% for FY2025, and the company reported net losses of $92.1m and $86.3m in the two 2026 quarters against profits of $49.5m and $42.5m a year earlier. The trailing twelve months is a GAAP loss of roughly $142.0m.
- The 2030 target requires a step-change nobody has demonstrated: at least $6.5bn of revenue and $1.3bn of Adjusted EBITDA implies a 20% margin against the 9–10% guided for 2026. Reaffirming a target three times is not the same as showing the operating leverage that delivers it.
- Debt has replaced a debt-free balance sheet, and dilution is masked: convertible senior notes went from zero at the end of FY2024 to $972.6m at the end of FY2025 and $1,365.3m at 30 June 2026. Because the 2026 quarters are loss-making, all dilutive instruments are antidilutive and drop out of the reported diluted count — which fell from 256.8m to 231.7m shares even as the underlying obligation grew.
- Manufacturer disintermediation is the structural threat: Eli Lilly launched its oral GLP-1 Foundayo across LillyDirect, Amazon Pharmacy, GoodRx, Ro and WeightWatchers on 9 April 2026 — pointedly not through Hims — and Lilly has stated it has no affiliation with the company. Novo runs its own NovoCare Pharmacy channel. Amazon bundled screening, prescription, monitoring and delivery through One Medical in April 2026.
3. Revenue Segments
Hims & Hers reports a single operating segment. The disaggregation it publishes changed in 2026: through FY2025 the company split revenue into Online and Wholesale, and from Q1 2026 it discloses only United States versus Rest of the World. Both are set out below, each on its own basis.
| Segment / category | % of revenue | What it is |
|---|---|---|
| United States | 82.6% in Q2 2026 ($621.8m); 94.3% for FY2025 | The core direct-to-consumer subscription business across all specialties. Grew 16% year on year in Q2 2026 after declining 8% in Q1 2026 on the weight-loss transition. |
| Rest of the world | 17.4% in Q2 2026 ($131.4m); 5.7% for FY2025 | United Kingdom, Germany, France, Ireland, Spain, Canada, Australia and Japan, assembled through the ZAVA, Medici and Eucalyptus acquisitions. Up more than sixteenfold year on year. |
| Online revenue | 98.5% of FY2025 ($2,311.4m); disclosure discontinued from 2026 | Subscription revenue billed directly to consumers on a recurring 30 or 90-day cadence, net of refunds, credits and chargebacks. |
| Wholesale revenue | 1.5% of FY2025 ($36.2m); disclosure discontinued from 2026 | Non-prescription product sold to retailers and third-party platforms. Shrinking in absolute terms, from $38.6m in FY2024. |
The company does not publish a revenue breakdown by specialty. What management has disclosed is that personalised offerings represented over 70% of United States revenue in 2025, against roughly half in 2024; that the Hers brand is on track to exceed $1bn of revenue in 2026; and that testosterone is the fastest-growing specialty outside weight loss and is expected to become the sixth United States specialty above a $100m annual run rate. Any specialty-level revenue table circulating elsewhere is a third-party estimate, not a company disclosure.
4. Business Model and Moat
How it makes money. A customer completes an online intake, is connected to a licensed provider through an affiliated professional medical corporation, and where a prescription is issued receives medication on an automatically billed recurring cadence. Around 98–99% of revenue is this online subscription flow. The company's own definition is explicit that subscribers are customers who have agreed to be automatically billed on a recurring basis at a defined cadence — which is precisely the mechanic the Federal Trade Commission's negative-option claims are aimed at.
Where the defensibility is claimed to sit. Vertical integration is the central argument. Hims owns and operates affiliated pharmacy and fulfilment facilities, a California peptide manufacturing plant acquired in February 2025, the Trybe Labs at-home testing facility acquired the same month, and YourBio Health's capillary blood-sampling technology. Owning the pharmacy lets the company control cost, formulation and delivery in a way a pure marketplace cannot, and $364.2m of property, equipment and software at 30 June 2026 is the balance-sheet evidence of it.
Personalisation, and its limits. The stated differentiator has been dosing and formulation tailored per patient. That claim carried the compounded-GLP-1 business through 2025, and it is also exactly what Novo Nordisk attacked in June 2025 as a false guise for mass compounding. After the 9 March 2026 strategic shift the personalisation pitch has migrated toward the flexible dosing and form factors already available within the branded assortment — a narrower and more durable version of the same argument.
The AI layer is the 2026 narrative. Since April 2026 the company has framed AI as the operating system for care: Labs AI launched on 7 May 2026, a rebuilt Hers app with a doctor-led AI-native care experience and a connected smart scale on 6 August 2026, and the Chief Financial Officer attributes meaningful cost efficiencies to it. Whether that constitutes a moat or a user interface is not yet answerable from the filings.
5. Financial Health
All figures below are taken from the company's own earnings releases and Form 10-K and 10-Q filings, and from its XBRL company facts on SEC EDGAR. Hims & Hers publishes Adjusted EBITDA and adjusted net income but does not publish an adjusted earnings per share figure.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | 271.9 | +82.8% | $(0.58) | $(0.58) † | Nil | $0m |
| FY2022 | 526.9 | +93.8% | $(0.32) | $(0.32) † | Nil | $0m |
| FY2023 | 872.0 | +65.5% | $(0.11) | $(0.11) † | Nil | $0m |
| FY2024 | 1,476.5 | +69.3% | $0.53 | $0.53 † | Nil | $0m |
| FY2025 | 2,347.6 | +59.0% | $0.51 | $0.51 † | Nil | $972.6m |
† Hims & Hers does not report an adjusted earnings per share figure. It reports Adjusted EBITDA of $(30.1)m, $(15.8)m, $49.5m, $176.9m and $318.0m for FY2021 to FY2025 respectively, and adjusted net income separately. The GAAP figure is repeated so the column is not left blank. ‡ The long-term debt column is convertible senior notes, net, per the XBRL tag ConvertibleDebtNoncurrent. The company was genuinely debt-free through FY2024; it issued $1.0bn of 0.00% convertible senior notes due 15 May 2030 in May 2025 and approximately $402.5m of 0.00% convertible notes due 2032 in May 2026, taking the carrying value to $1,365.3m at 30 June 2026.
| Quarter / Half | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q2 2026 (to 30 Jun 2026) | 753.2 | $(0.37) † | $(0.37) |
| Q1 2026 (to 31 Mar 2026) | 608.1 | $(0.40) † | $(0.40) |
| Q4 2025 (to 31 Dec 2025) | 617.8 | $0.08 † | $0.08 |
| Q3 2025 (to 30 Sep 2025) | 599.0 | $0.06 † | $0.06 |
| FY2025 total | 2,347.6 | $0.51 † | $0.51 |
The corresponding Adjusted EBITDA figures are $60.3m for Q2 2026, $44.3m for Q1 2026, $66.3m for Q4 2025 and $78.4m for Q3 2025, giving $249.3m for the trailing twelve months against $318.0m for FY2025. The swing to a GAAP loss in Q2 2026 is largely identifiable: legal contingencies of $47.5m in the quarter and $62.5m for the half, acquisition and transaction costs of $28.8m, restructuring of $4.6m, and depreciation and amortisation tripling to $29.5m on the Eucalyptus intangibles. General and administrative expense rose from $67.3m to $165.4m year on year. Separately, Q1 2026 absorbed a $28.5m non-cash inventory write-down inside cost of revenue as the compounded-GLP-1 inventory was written off.
On cash: FY2025 operating cash flow was $300.0m against capital expenditure of $242.6m, giving free cash flow of $57.4m. For the trailing twelve months to 30 June 2026, operating cash flow was $263.5m and capital expenditure $201.8m, giving free cash flow of approximately $61.7m. The first half of 2026 was free-cash-flow negative at minus $15.2m. At 30 June 2026 the company held $609.8m of cash and $231.2m of short-term investments against $1,365.3m of convertible notes; total stockholders' equity had fallen from $540.9m at the end of 2025 to $324.1m, and goodwill had risen from $278m to $1,101.7m on the Eucalyptus acquisition. A further $537.4m of current and $165.6m of non-current deferred acquisition payable, plus $81.4m current and $81.6m non-current earn-out consideration, sits on the balance sheet as the unpaid portion of that deal.
6. Valuation Metrics
Raw metrics, September 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$6.64bn at $28.44 per share, the close on 1 September 2026, across 233.3m Class A and Class V shares |
| Trailing P/E (GAAP) | n/m — the trailing twelve months to 30 June 2026 produced a GAAP net loss of approximately $142.0m (Q3 2025 +$15.8m, Q4 2025 +$20.6m, Q1 2026 −$92.1m, Q2 2026 −$86.3m), so there are no trailing earnings to capitalise. On FY2025 GAAP diluted EPS of $0.51 the historic multiple would have been ~55.8x. The company publishes no adjusted EPS. |
| P/E (forward) | ~28.4x on a consensus forward EPS of approximately $1.00. Hims & Hers guides revenue and Adjusted EBITDA only and issues no EPS guidance, so this is a third-party consensus input rather than a company figure. |
| P/S (TTM) | 2.57x (market cap ~$6.64bn / trailing twelve-month revenue $2,578.1m, being Q3 2025 $599.0m + Q4 2025 $617.8m + Q1 2026 $608.1m + Q2 2026 $753.2m) |
| Enterprise value | ~$7.16bn (market cap ~$6.64bn + convertible senior notes $1,365.3m − cash $609.8m and short-term investments $231.2m, per the 30 June 2026 balance sheet). Treating the $703.0m of deferred acquisition payable and $163.0m of earn-out consideration as debt-like would take enterprise value to roughly $8.0bn. |
| EV/EBITDA (TTM) | n/m on a GAAP basis — trailing operating income is a loss of approximately $154.5m, which even after adding back $87.2m of depreciation and amortisation leaves EBITDA negative at roughly −$67.3m. On the company's own Adjusted EBITDA of $249.3m for the trailing twelve months the multiple is ~28.7x, and on the $300m midpoint of 2026 guidance it is ~23.9x. Adjusted EBITDA excludes stock-based compensation, the $62.5m of legal contingencies and $38.1m of restructuring charges booked in the first half. |
| P/FCF | ~108x (market cap ~$6.64bn / free cash flow ~$61.7m; free cash flow = trailing operating cash flow $263.5m − capital expenditure $201.8m). On FY2025 free cash flow of $57.4m the multiple would be ~116x. The first half of 2026 was free-cash-flow negative. |
| 52-week high | $65.30 |
| 52-week low | $13.74 |
| Short interest (% of float) | ~27.5% — 58,674,597 shares short at the 14 August 2026 settlement date against a float of 213,682,422 shares. One of the most heavily shorted mid-caps on the New York Stock Exchange, though down from a reported peak of roughly 43% of float earlier in 2026. |
| Days to cover | ~4.0 days on the trailing average daily volume used by the primary data provider; a second provider computes 5.51 days for the same 14 August 2026 settlement. Either figure implies genuine two-way squeeze risk on news. |
7. What Are They Building
An international platform, bought rather than built. The 2025 and 2026 acquisitions are the strategy. ZAVA, completed by 9 July 2025, brought the United Kingdom, Germany, France, Ireland and Spain. Medici Technologies, acquired in November 2025, brought Canada. Eucalyptus, announced in February 2026 at $1.15bn and completed on 2 June 2026, brought Australia and Japan and deepened the United Kingdom, Germany and Canada. The Hims brand launched to Australian consumers on 31 August 2026, the first visible commercial output of that deal.
Diagnostics as an acquisition funnel. Trybe Labs, a New Jersey at-home lab-testing facility acquired in February 2025, and YourBio Health's capillary whole-blood sampling technology underpin the Labs by Hims & Hers product launched on 13 November 2025 and the Labs AI care agent launched on 7 May 2026. The logic is that a cheap whole-body test both acquires the customer and identifies which specialties to sell them.
Peptides. The California peptide manufacturing facility acquired in February 2025 is a manufacturing asset whose value depends directly on how the Food and Drug Administration regulates peptide therapy. The company has published three policy posts on the subject in 2026 — applauding regulatory clarity in April, welcoming progress on a safer access pathway in July, and defending peptides as a class the same month. This is an open regulatory front with a plant attached to it.
Generic GLP-1 arbitrage. On 21 May 2026 Hims launched access to generic semaglutide for Canadian customers, following it on 29 May with a price reduction. Canada was chosen explicitly as one of the first markets expected to have generic semaglutide. As patents expire in other jurisdictions the same play becomes available — a lawful version of the compounding economics the company lost in the United States.
8. Competitive Position
| Peer | Market cap (September 2026) | Key 2025/2026 metric |
|---|---|---|
| Eli Lilly (LLY) | ~$1,034bn | Launched the oral GLP-1 Foundayo across the United States from 9 April 2026 through LillyDirect, Amazon Pharmacy, GoodRx, Ro and WeightWatchers. Lilly has stated it has no affiliation with Hims & Hers. Trailing twelve-month revenue $79.7bn. |
| Novo Nordisk (NVO) | ~$199bn | Trailing twelve-month revenue $329.4bn Danish kroner equivalent as reported by the data provider. Runs NovoCare Pharmacy, its own direct-to-consumer self-pay channel, while simultaneously supplying branded Ozempic and Wegovy to the Hims platform under the 9 March 2026 arrangement. |
| Teladoc Health (TDOC) | ~$1.14bn | Trailing twelve-month revenue $2.49bn, marginally below Hims & Hers on a comparable basis, but contracting: revenue declined roughly 2% year on year in Q2 2026. The incumbent telehealth platform, now smaller by market value than Hims by a factor of nearly six. |
| LifeMD (LFMD) | ~$149m | Q2 2026 revenue $47.3m with a GAAP loss of $(0.16) per share, and full-year 2026 guidance cut to revenue of $205.5–212.5m and Adjusted EBITDA of minus $6.0m to breakeven, from $220–230m and plus $12–17m previously. |
| Amazon (AMZN) | ~$2,750bn | Bundled GLP-1 screening, prescription, monitoring and pharmacy delivery through One Medical in April 2026, with same-day delivery in nearly 3,000 areas expanding to 4,500 municipalities by the end of 2026. Also the fulfilment partner for LillyDirect home delivery. |
| Ro | Private — last disclosed valuation $7bn (February 2022) | A distribution partner for Eli Lilly's Foundayo through LillyDirect from 9 April 2026, a channel Hims & Hers does not have. Approximately $1.03bn raised in total. |
The competitive read in 2026 is that the threat is not other telehealth start-ups — Teladoc is shrinking and LifeMD has just cut guidance — but manufacturer disintermediation. Novo and Lilly both now sell direct to patients, and Amazon has bundled the entire stack from screening to delivery. Hims & Hers' answer is scale, international breadth and an AI-native experience rather than price. WeightWatchers, which filed a prepackaged Chapter 11 in May 2025 and emerged as a private entity on 24 June 2025 having eliminated $1.15bn of debt, is also now a LillyDirect distribution partner.
9. Insider Activity
Chief Executive Andrew Dudum remains the company's largest individual holder, with roughly 8.23 million shares across direct and trust holdings after the August 2026 transfers. Insider activity in 2026 is entirely one-directional: zero open-market purchases by any insider, and every discretionary sale executed under a Rule 10b5-1 plan. The two very large August movements by Dudum are estate-planning transfers at zero consideration, not sales, and should not be read as selling.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Andrew Dudum, CEO and Director | 27 Aug 2026 | Trust distribution (J) | 977,566 Class A | Nil | Nil — no consideration | Not under a plan; estate planning |
| Andrew Dudum, CEO and Director | 25 Aug 2026 | Bona fide gift (G) | 463,289 Class A | Nil | Nil — no consideration | Not under a plan; estate planning |
| Soleil Boughton, Chief Legal Officer | 19 Aug 2026 | Sale (S) | 25,111 Class A | $27.55 | $691,808 | Rule 10b5-1 adopted 21 May 2026 |
| Oluyemi Okupe, CFO | 19 Aug 2026 | Option exercise and sale (M/S) | 4,938 Class A | $29.99 weighted average | $148,092 | Rule 10b5-1 adopted 21 May 2025 |
| Deborah Autor, Chief Policy Officer and Director | 18 Aug 2026 | Sale (S) | 16,773 Class A | $27.85 | $467,128 | Rule 10b5-1 adopted 20 May 2026 |
| Andrew Dudum, CEO and Director | 14 Aug 2026 | Tax withholding on vesting | 78,859 Class A | ~$27.90 | ~$2.2m | Non-discretionary |
| Oluyemi Okupe, CFO | 17 Jul 2026 | Option exercise and sale (M/S) | 7,163 Class A | $31.99 weighted average | $229,167 | Rule 10b5-1 adopted 21 May 2025 |
| Dr Patrick Carroll, Global Chief Medical Officer | 18 Jun 2026 | Sale (S) | 23,726 Class A | $35.00 | $830,410 | Rule 10b5-1 |
The realised prices trace the year: $36.49 on 6 July, $31.99 on 17 July, then $27.55 to $30.00 across 18 and 19 August. Insiders have been selling into a falling tape under plans adopted in May, before the Federal Trade Commission action. One governance point is worth flagging alongside this: Chief Accounting Officer Irene Becklund is departing in October 2026, with Chief Financial Officer Yemi Okupe assuming those responsibilities on an interim basis, at the same time as an SEC enforcement investigation into the company's disclosures is live.
10. Key Risks
- Material litigation and enforcement: the Federal Trade Commission, joined by the State of Utah and Los Angeles County on behalf of the People of California, filed suit in the Northern District of California on 29 July 2026 seeking a permanent injunction, monetary relief, disgorgement of profits and civil penalties under Section 5 of the FTC Act and the Restore Online Shoppers' Confidence Act. Running alongside it are an SEC Division of Enforcement investigation into the company's disclosures on compounded semaglutide, disclosed in the FY2025 Form 10-K, and a Department of Justice referral announced by the Department of Health and Human Services General Counsel in February 2026. Together these attack the subscription billing mechanic, the data practices and the public statements simultaneously.
- Regulatory closure of the compounding pathway: the Food and Drug Administration issued more than 50 warning letters to telehealth firms and compounders in March 2026 and has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, with the comment docket closed on 29 June 2026. If finalised, large-scale compounding of all three molecules is permanently foreclosed.
- Payment-processor sanction: Hims & Hers was enrolled in Visa's Acquirer Monitoring Program in August 2026 after July card-dispute rates in the weight-loss subscription business breached Visa's 1.5% threshold. The weight-loss business generated 75% of disputes. The company must hold below the threshold for three consecutive months to exit, and pays an $8 surcharge per dispute.
- Margin compression is structural, not one-off: gross margin has fallen from 82% in FY2023 to 79%, then 74%, then 64% in Q2 2026. Selling branded Novo GLP-1s at prices matching other telehealth firms is a materially lower-margin activity than compounding was, and the mix is shifting toward it.
- Integration and acquisition risk: goodwill quadrupled to $1,101.7m in six months on the $1.15bn Eucalyptus deal, against total stockholders' equity of $324.1m. A further $703.0m of deferred acquisition payable and $163.0m of earn-out consideration remains unpaid. An impairment against that goodwill would exceed the entire equity base.
- Supplier concentration and counterparty history: the branded GLP-1 supply that now underpins the United States weight-loss business comes from a counterparty that publicly accused the company of illegal mass compounding and deceptive marketing in June 2025 and sued it for patent infringement in February 2026. That suit was dismissed without prejudice, meaning it can be refiled.
- Securities class-action exposure: putative class actions filed in 2025 on behalf of purchasers between 29 April and 23 June 2025 remain in active litigation with no class certified and no settlement announced, and a fresh wave of investigations opened after the FTC filing, including a Pomerantz investor alert dated 1 September 2026.
- Dilution obscured by loss-making periods: $1,365.3m of zero-coupon convertible notes and outstanding equity awards drop out of the reported diluted share count while the company is loss-making, which is why the diluted count fell from 256.8m to 231.7m shares year on year. The obligation has not gone away; only its visibility in the earnings-per-share denominator has.
11. Recent Developments
- 09 Mar 2026 — Strategic shift on United States weight loss, and peace with Novo Nordisk. Hims announced access to branded Ozempic and Wegovy injections and tablets, agreed to stop advertising compounded GLP-1s entirely, and Novo Nordisk simultaneously dismissed its patent lawsuit without prejudice.
- 23 Apr 2026 — Full range of FDA-approved GLP-1s live on the platform. Completion of the March transition, with the branded assortment fully available.
- 07 May 2026 — Labs AI launched. The company's first AI care agent, layered on the diagnostics business built from the Trybe Labs and YourBio acquisitions.
- 11 May 2026 — Q1 2026 results. Revenue of $608.1m grew only 4%, the company reported its first quarterly GAAP loss in years at $(92.1)m or $(0.40) per share, gross margin fell to 65%, and full-year revenue guidance was nonetheless raised to $2.8–3.0bn. The company also moved from a quarterly to an annual shareholder letter.
- 21 May 2026 — Generic semaglutide launched in Canada. Followed on 29 May by a price reduction, exploiting Canada's earlier patent expiry.
- 02 Jun 2026 — Eucalyptus acquisition completed for $1.15bn. Adds Australia and Japan and deepens the United Kingdom, Germany and Canada. Goodwill quadrupled to $1.10bn as a result.
- 29 Jul 2026 — Federal Trade Commission sues, and the shares fall 14.73%. The FTC, Utah and Los Angeles County filed in the Northern District of California over health-data sharing with Meta and Snap, obscured cancellation flows, and charging customers before a provider consultation. The stock closed at $25.00.
- 06 Aug 2026 — New Hers app launched. A doctor-led, AI-native care experience including an AI-powered weight-loss programme with a connected smart scale.
- 10 Aug 2026 — Q2 2026 results and a guidance raise. Revenue of $753.2m grew 38%, subscribers reached 2.89 million, Adjusted EBITDA was $60.3m and the net loss $(86.3)m. International revenue rose more than sixteenfold to $131.4m and full-year guidance was raised to $3.1–3.3bn.
- 24 Aug 2026 — Visa places the company under monitoring. Enrolment in the Acquirer Monitoring Program after July card-dispute rates in weight-loss subscriptions exceeded Visa's threshold, with roughly $75,000 of surcharges falling due in September. The shares slumped.
- 31 Aug 2026 — Hims launches to consumers in Australia. The first visible commercial output of the Eucalyptus acquisition.
- 01 Sep 2026 — A fresh securities-litigation front opens. Pomerantz LLP issued an investor alert announcing an investigation of claims on behalf of Hims & Hers investors, joining several other firms with open investigations following the FTC action.
12. Key Dates to Watch
- Expected Sep 2026 — first Visa dispute-surcharge invoice of approximately $75,000 falls due, and the first of three consecutive months in which the card-dispute rate must be held below 1.5% for the company to exit the Acquirer Monitoring Program
- Expected Oct 2026 — the customary press release confirming the Q3 2026 reporting date, on the pattern of the 13 October 2025 announcement for the Q3 2025 results. Chief Accounting Officer Irene Becklund also departs during October 2026.
- Expected Nov 2026 — Q3 2026 results. Third-party earnings calendars indicate around 9 November 2026; this is a consensus estimate and has not been confirmed by the company. Q3 2025 was reported on 3 November 2025. Guidance for the quarter is revenue of $880–900m and Adjusted EBITDA of $75–95m.
- Expected Feb 2027 — Q4 and FY2026 results and the FY2026 Form 10-K, on the pattern of the 23 February 2026 release. This is now also the annual shareholder letter, following the move away from quarterly letters announced in May 2026.
- 15 Nov 2029 — holders of the $1.0bn of 0.00% convertible senior notes may convert at will from this date
- 15 May 2030 — maturity of the $1.0bn of 0.00% convertible senior notes; a further approximately $402.5m of 0.00% notes mature in 2032
- TBD — case-management and hearing dates in FTC v. Hims & Hers Health, Inc. in the Northern District of California, filed 29 July 2026. No schedule has been published.
- TBD — final Food and Drug Administration determination on excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List. The comment docket closed on 29 June 2026 and no decision date has been announced.
Three matters are open-ended with no timetable disclosed: the SEC Division of Enforcement investigation, on which the company states it is unable to predict when or how the matter will be concluded; the Department of Justice referral; and class certification in the 2025 securities actions. The deferred acquisition payable and earn-out consideration from the Eucalyptus deal also have no disclosed settlement dates. Readers tracking the schedule may find the ChartsView Economic Calendar useful, and discussion continues on the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 6 September 2026
Rocket Pharmaceuticals is a Cranbury, New Jersey gene-therapy developer that spent eight years and roughly $1.4bn of cumulative losses getting a first medicine approved — and reached that milestone in March 2026 with a market capitalisation of under half a billion dollars. The company sits at an unusual junction. It now owns an FDA-approved therapy, KRESLADI, and has already converted the priority review voucher that came with it into $180m of cash. It has also just restarted the pivotal trial that a patient death shut down in May 2025, with three patients through the safety window and no repeat of the complication. Against that, it still recognises no revenue at all, burns roughly $170m a year, and trades at an enterprise value materially below the cash on its balance sheet. This report sets out what the filings say, without opinions on whether the shares are cheap.
1. Company Snapshot
| Field | Value |
|---|---|
| Legal name | Rocket Pharmaceuticals, Inc. |
| Ticker / exchange | RCKT, Nasdaq Global Market |
| Headquarters | Cranbury, New Jersey, United States |
| Sector | Healthcare — clinical-stage gene therapy (AAV and lentiviral) |
| Market cap | ~$424m (109.8m shares at the $3.86 close on 4 September 2026) |
| Revenue (FY2025) | $0m — no revenue recognised in any year since 2018 |
| Net loss (FY2025) | $223.1m, or $(2.01) per diluted share |
| Cash and investments | $283.7m at 30 June 2026; runway guided into Q2 2028 |
| Borrowings | Nil. No debt outstanding since 2021 |
| Employees | 202 full-time at 31 December 2025 (195 US, 6 Spain, 1 Italy) |
| CEO / Leadership | Gaurav Shah, M.D., co-founder and Chief Executive Officer since January 2018; Aaron Ondrey, Chief Financial Officer since March 2024 |
| Approved products | One — KRESLADI (marnetegragene autotemcel), accelerated approval 27 March 2026 |
Sources: Rocket Pharmaceuticals FY2025 Form 10-K (filed 26 February 2026), Q2 2026 results release (10 August 2026), and SEC XBRL company facts.
2. Bull Case and Bear Case
Bull Case
- An approval finally in hand: KRESLADI received FDA accelerated approval on 27 March 2026 for paediatric severe leukocyte adhesion deficiency-I, after a June 2024 complete response letter on manufacturing. Eight years of platform work now has a regulatory precedent behind it.
- The voucher was monetised immediately: the rare paediatric disease priority review voucher awarded on approval was sold for $180m gross, closing 12 June 2026. That is non-dilutive cash worth roughly 42% of the entire current market capitalisation.
- Danon is back on track with clean safety: all three patients dosed under the modified Phase 2 protocol at the recalibrated 3.8x10^13 GC/kg dose completed the protocol-defined observation period with no thrombotic microangiopathy and no capillary leak syndrome — the exact complication that caused the May 2025 hold.
- Enterprise value below net cash: with $283.7m of cash and investments, no borrowings and a $424m market capitalisation, the enterprise value is roughly $140m. The market is currently attributing very little to an approved product plus four clinical programmes.
- Cost base cut hard and runway extended: the July 2025 reorganisation removed about 30% of staff; FY2025 R&D fell to $142.0m from $171.2m and G&A to $86.5m from $102.0m. Guided runway moved from "into Q2 2027" in February 2026 to "into Q2 2028" by August 2026.
Bear Case
- Still no revenue whatsoever: the income statement has shown $0 of revenue every year from 2018 through 2025, and KRESLADI patient onboarding is not expected to begin until Q4 2026. LAD-I is an ultra-rare condition, so even a successful launch will not produce meaningful scale.
- Danon is not de-risked, only restarted: Rocket is still "engaging the FDA" on dosing additional patients. Three patients is a small safety sample, and a further serious adverse event in the lead programme would be difficult to recover from.
- The AAV sector is in a sentiment downturn: Sarepta's Elevidys deaths, the FDA's suspension request and its revocation of Sarepta's platform-technology designation have chilled investor appetite for adeno-associated virus gene therapy across the board through 2025 and 2026.
- Burn still exceeds the balance sheet on a two-year view: trailing twelve-month operating cash outflow was $170.3m against $283.7m of cash. A $100m at-the-market equity facility with Cantor Fitzgerald was put in place in March 2026, and at a $3.86 share price any use of it is heavily dilutive.
- Optionality was deliberately narrowed: the Fanconi anaemia programme lost its EU marketing application in July 2025 and its US biologics licence application in October 2025, and the pyruvate kinase deficiency programme was deprioritised. Two late-stage shots on goal were removed to fund the cardiovascular platform.
3. Revenue Segments
Rocket manages the business as a single operating segment and recognises no revenue, so the table below sets out the therapeutic categories the company reports against rather than a revenue split. Every line is currently 0% of revenue.
| Segment / category | % of revenue | What it is |
|---|---|---|
| AAV cardiovascular platform | 0% — no revenue recognised | The company's declared strategic priority since July 2025. Adeno-associated virus therapies delivered by intravenous infusion for inherited cardiomyopathies: RP-A501 (Danon disease), RP-A601 (PKP2-ACM) and RP-A701 (BAG3-DCM). |
| Lentiviral haematology — commercial | 0% — no revenue recognised | KRESLADI (marnetegragene autotemcel), the approved ex vivo lentiviral therapy for paediatric severe LAD-I. Commercial availability and patient onboarding anticipated to begin in Q4 2026 through a limited network of qualified treatment centres. |
| Lentiviral haematology — deprioritised | 0% — no revenue recognised | RP-L102 for Fanconi anaemia (both regulatory filings withdrawn in 2025, partnering under consideration) and RP-L301 for pyruvate kinase deficiency (Phase 1 complete, RMAT designated, no committed timeline). |
| Non-operating cash generation | 0% — recorded as other income, not revenue | The $180m sale of the KRESLADI priority review voucher, which closed on 12 June 2026 and produced a $178.2m gain in the Q2 2026 income statement. Voucher sales are one-off and are not classified as revenue. |
4. Business Model and Moat
How it makes money. Today, it does not. Rocket has no product revenue, no collaboration revenue and no royalty stream. Every dollar spent since 2018 has been funded by equity issuance, and more recently by the one-off $180m voucher sale. The intended model is orphan-drug economics: single-administration curative gene therapies for conditions affecting a few thousand people worldwide, priced in the seven figures per patient and delivered through a small number of specialist treatment centres. KRESLADI is the first test of whether that model closes for Rocket.
What the moat is supposed to be. Two things. First, manufacturing: Rocket built its own 50,000 sq ft AAV cGMP facility inside a 103,720 sq ft Cranbury campus, which matters because the June 2024 complete response letter on KRESLADI was a chemistry-and-manufacturing rejection, not an efficacy one. Owning the process is what allowed the resubmission. Second, disease selection: the company deliberately targets monogenic conditions where the causal gene is unambiguous and there is either no approved therapy or only a transplant option, which limits the number of competitors willing to invest.
Why the moat is contested. Regulatory precedent in AAV gene therapy is not owned by anyone, and the FDA demonstrated in 2025 that a platform-technology designation can be revoked. Rocket's remaining defensive asset is therefore its data and its manufacturing know-how rather than any structural barrier. In practice, the binding constraint is capital: a clinical-stage company with a two-year cash runway competes for the same rare-disease patients as Ultragenyx and Krystal Biotech, both of which already fund development from product revenue.
5. Financial Health
Rocket has never recognised revenue. The annual series below is therefore a loss-and-liquidity table rather than a growth table, and the per-share figures are the meaningful line. All figures are taken from the company's own results releases and from SEC XBRL company facts filed with the Form 10-K.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | $0m | n/a | $(2.67) | $(2.67)† | Nil | $0m‡ |
| FY2022 | $0m | n/a | $(3.26) | $(3.26)† | Nil | $0m‡ |
| FY2023 | $0m | n/a | $(2.92) | $(2.92)† | Nil | $0m‡ |
| FY2024 | $0m | n/a | $(2.73) | $(2.73)† | Nil | $0m‡ |
| FY2025 | $0m | n/a | $(2.01) | $(2.01)† | Nil | $0m‡ |
† Rocket publishes no adjusted or non-GAAP earnings measure in any period. The GAAP figure is repeated so the column is not left blank.
‡ Rocket has had no borrowings outstanding since its convertible notes were extinguished during 2021 (the XBRL convertible-note balance falls to zero at 30 June 2021 and stays there). The balance sheet does carry a finance-lease obligation on the Cranbury facility of $21.3m at 30 June 2026 and operating-lease liabilities of $3.5m; neither is debt in the borrowing sense. Aggregator "total debt" figures of roughly $24.8m are that lease total.
| Quarter / Half | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q2 2026 (to 30 Jun 2026) | $0m | $1.08† | $1.08 |
| Q1 2026 (to 31 Mar 2026) | $0m | $(0.42)† | $(0.42) |
| Q4 2025 (to 31 Dec 2025) | $0m | $(0.38)† | $(0.38) |
| Q3 2025 (to 30 Sep 2025) | $0m | $(0.45)† | $(0.45) |
| Q2 2025 (to 30 Jun 2025) | $0m | $(0.62)† | $(0.62) |
| FY2025 total | $0m | $(2.01)† | $(2.01) |
The Q2 2026 profit is entirely non-operating. Reported net income was $123.2m, driven by a $178.2m gain on the priority review voucher sale; underneath it, R&D was $29.5m and G&A $17.4m, both sharply below the $42.7m and $25.0m of Q2 2025. Basic EPS was $1.09 and diluted $1.08. On a trailing twelve-month basis the company remains loss-making at $(0.17) per diluted share, and generated an operating cash outflow of $170.3m against capital expenditure of only $0.1m. Depreciation and amortisation over the same twelve months was $7.6m. Cash and investments moved from $188.9m at 31 December 2025 to $144.4m at 31 March 2026 and then to $283.7m at 30 June 2026 on receipt of the voucher proceeds.
6. Valuation Metrics
Raw metrics, September 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$424m (109,774,597 shares at the $3.86 close on 4 September 2026) |
| Enterprise value | ~$140m (market cap ~$424m + borrowings $0m − cash and short-term investments $283.7m per the 30 June 2026 balance sheet). Enterprise value sits below net cash because the equity is capitalised at less than the cash it holds plus a negative value for the burn. |
| Trailing P/E (GAAP) | n/m — trailing twelve-month diluted EPS is $(0.17), a loss. The only profitable quarter in the series, Q2 2026, was produced by a one-off $178.2m voucher gain rather than by operations. |
| P/E (forward) | n/m — consensus forward EPS is $(1.30), a loss. Rocket issues no earnings guidance. |
| P/S (TTM) | n/m — the company recognises no revenue, so the ratio has no denominator. |
| EV/EBITDA (TTM) | n/m — trailing twelve-month EBITDA is negative $184.0m (operating loss $191.6m plus depreciation and amortisation of $7.6m, the wider cash-flow-statement figure). A negative denominator makes the multiple meaningless. |
| P/FCF | n/m — trailing twelve-month free cash flow is negative $170.4m (operating cash flow $(170.3)m less capital expenditure of $0.1m). Capital spending has collapsed from $16.4m in FY2023 to $0.4m in FY2025 as the build-out finished. |
| 52-week high | $5.45 intraday; $5.30 on a closing basis |
| 52-week low | $2.53 intraday; $2.60 on a closing basis |
| Short interest (% of float) | 16.4% (14,391,319 shares short against a 87,545,241-share free float), settlement date 14 August 2026. Short interest has roughly doubled as a proportion of the float over the past twelve months. |
| Days to cover | 9.7 days on the same 14 August 2026 settlement, using average daily volume. This is unusually high and reflects thin liquidity rather than a large absolute short position. |
| Price/book | ~1.1x (market cap ~$424m against shareholders' equity of $368.8m at 30 June 2026) |
Price action can be followed on the ChartsView Live Charts page.
7. What Are They Building
RP-A501 for Danon disease. The lead asset and the reason the share price is where it is. An AAV9 gene therapy delivered by single intravenous infusion for an X-linked cardiomyopathy that typically kills male patients in their teens or twenties without a heart transplant. On 23 May 2025 the FDA placed the pivotal Phase 2 trial on clinical hold after a treated patient developed capillary leak syndrome with complement activation and subsequently died of an acute systemic infection. Rocket's investigation pointed at a novel immunosuppressive agent that had been added to the pre-treatment regimen specifically for the AAV9 Danon programme. The FDA lifted the hold on 20 August 2025, under three months later, authorising resumption at a recalibrated dose of 3.8x10^13 GC/kg in three sequential patients with a minimum four-week interval and an immunomodulatory regimen closer to the earlier paediatric cohort. All three were dosed and, as disclosed on 10 August 2026, all three cleared the protocol-defined observation window with no thrombotic microangiopathy and no capillary leak syndrome. A global natural history study has now enrolled more than 50 patients.
KRESLADI for LAD-I. Approved on 27 March 2026 under accelerated approval for paediatric patients with severe leukocyte adhesion deficiency-I caused by biallelic ITGB2 variants who lack an HLA-matched sibling donor. This is an ex vivo lentiviral therapy: the patient's own haematopoietic stem cells are harvested, corrected and reinfused. The route to approval was not smooth — the FDA issued a complete response letter in June 2024 over chemistry and manufacturing deficiencies, and the resubmission was only accepted in October 2025 with a 28 March 2026 goal date.
RP-A601 for PKP2-ACM. A Phase 1 AAV programme in plakophilin-2 arrhythmogenic cardiomyopathy, still enrolling to cover a broader severity range. Data presented at the American Society of Gene and Cell Therapy meeting in May 2025, from an April 2025 cutoff, showed increased PKP2 protein expression on cardiac biopsy in all three initial patients, improved desmosomal localisation, directional improvements in arrhythmia measures and right-ventricular function, and no dose-limiting toxicities through up to twelve months of follow-up. An FDA update on pivotal study design is guided for the second half of 2026.
RP-A701 for BAG3 dilated cardiomyopathy. The newest programme, using an AAVrh.74 capsid. The IND was cleared in 2025 and screening is under way for a multicentre dose-escalation study in adults; first patient dosing is now guided for the second half of 2026, having previously been indicated for mid-2026. BAG3-associated dilated cardiomyopathy is estimated to affect around 30,000 people in the United States with no disease-specific approved therapy. The programme arrived with the December 2022 acquisition of Renovacor and its Temple University licence.
What is no longer being built. RP-L102 for Fanconi anaemia lost its European marketing authorisation application in July 2025 and its US biologics licence application in October 2025, in both cases by voluntary withdrawal for strategic rather than safety reasons; Rocket says it will consider external partnerships. RP-L301 for pyruvate kinase deficiency completed Phase 1 with RMAT designation and encouraging haemoglobin responses in the paediatric cohort, but carries no committed development timeline.
8. Competitive Landscape
| Peer | Market cap (September 2026) | Key 2025/2026 metric |
|---|---|---|
| Krystal Biotech (KRYS) | ~$10.6bn | Trailing revenue of ~$440m from VYJUVEK, the approved topical gene therapy for dystrophic epidermolysis bullosa. The clearest illustration of what a commercialised rare-disease gene therapy is worth relative to a pre-revenue one. |
| uniQure (QURE) | ~$3.1bn | Trailing revenue of ~$19m. The nearest large AAV-focused pure-play, with programmes in Huntington's disease and haemophilia B; valued at more than seven times Rocket on a comparable pre-commercial revenue base. |
| Beam Therapeutics (BEAM) | ~$3.1bn | Trailing revenue of ~$156m, almost all collaboration income. A base-editing platform company rather than a conventional AAV developer, included as the benchmark for what platform optionality is priced at. |
| Sarepta Therapeutics (SRPT) | ~$2.4bn | Trailing revenue of ~$1.97bn, yet capitalised at under 1.3x sales after the FDA requested suspension of Elevidys distribution, placed limb-girdle trials on hold following three patient deaths, revoked the company's platform-technology designation, and the company cut roughly 36% of staff. |
| Ultragenyx Pharmaceutical (RARE) | ~$1.5bn | Trailing revenue of ~$717m across multiple approved rare-disease products. A diversified commercial rare-disease company now capitalised at roughly twice Rocket's cash balance. |
The read-across from Sarepta matters more than the individual comparisons. A company with nearly $2bn of revenue trading at 1.3 times sales tells you what the market currently pays for AAV gene-therapy risk after a cluster of patient deaths. Rocket's own clinical hold arrived in the same window, and its equity has re-rated to an enterprise value below net cash as a result. Set against that, Krystal at roughly 24 times sales shows the sector is not uniformly derated — commercialised, safe and growing is still valued generously.
9. Insider Activity
Chief Executive Gaurav Shah, who co-founded Rocket and has led it since January 2018, is the only named officer with disclosed 2026 Form 4 activity found in this review. All of the transactions below are dispositions connected to equity compensation rather than discretionary open-market selling: two are shares withheld or sold to satisfy tax on restricted stock unit vesting, and the third covers the exercise cost and tax on an option exercise that simultaneously increased his holding by 76,490 shares. No open-market purchases by any insider were identified.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Gaurav Shah (CEO) | 18 Aug 2026 | Disposition | 2,293 | $3.381 | ~$7,753 | RSU tax withholding |
| Gaurav Shah (CEO) | 13 Aug 2026 | Disposition | 2,837 | $3.381 | ~$9,592 | RSU tax withholding |
| Gaurav Shah (CEO) | 21 May 2026 | Sale to cover | 55,684 | ~$3.09 | ~$171,840 | Option exercise cost and tax |
| Gaurav Shah (CEO) | 21 May 2026 | Acquisition | 76,490 | Exercise price | ~$129,344 | Stock option exercise |
Shares outstanding have grown steadily from 106,453,818 at 31 December 2024 to 109,539,424 at 30 June 2026 — a little under 3% over eighteen months, which is modest for a pre-revenue biotech and reflects the fact that the December 2024 offering and pre-funded warrant placement, not 2026 issuance, did the heavy lifting.
10. Key Risks
- Liquidity and dilution: Rocket recognises no revenue and burned $170.3m of operating cash over the last twelve months against $283.7m of cash and investments. Guided runway reaches into Q2 2028, which means a financing decision arrives well before the Danon programme could plausibly be approved. A $100m at-the-market facility with Cantor Fitzgerald has been in place since March 2026, and issuing equity near a $3.86 share price would be materially dilutive.
- Repeat safety events in the lead programme: the May 2025 patient death produced a three-month clinical hold and a permanent reset of the Danon protocol. Only three patients have been dosed under the revised regimen. A further serious adverse event would very likely end the programme that accounts for most of the equity's optionality.
- Regulatory pathway not yet agreed: the FDA lifted the hold but Rocket is still "engaging" the agency on dosing additional patients and completing the pivotal trial. The size, endpoints and duration of that trial are undetermined, and the guided update is only a general commitment to the second half of 2026.
- Commercial execution on an ultra-rare indication: KRESLADI treats a condition affecting a very small number of children. Patient onboarding does not begin until Q4 2026, will run through a limited network of qualified treatment centres, and depends on payer reimbursement for a one-time high-cost therapy. Approval does not guarantee uptake.
- Sector-wide AAV sentiment and FDA posture: the Sarepta episode showed the FDA is willing to suspend distribution of an approved gene therapy, halt multiple trials and revoke a platform designation. That regulatory temperature applies to Rocket's entire cardiovascular pipeline regardless of its own data.
- Concentrated pipeline after the reorganisation: the July 2025 restructuring removed about 30% of the workforce and shelved the Fanconi anaemia and pyruvate kinase deficiency programmes. The company is now effectively a bet on three AAV cardiac assets plus one approved ultra-orphan product.
- Thin liquidity and elevated short interest: 16.4% of the free float is sold short with 9.7 days to cover. In a sub-$500m company that combination amplifies moves in both directions and can make orderly financing harder.
11. Recent Developments
- 10 Aug 2026 — Q2 2026 results and a clean Danon safety readout. Net income of $123.2m ($1.09 basic, $1.08 diluted) driven by the $178.2m voucher gain; R&D down to $29.5m and G&A to $17.4m; cash and investments $283.7m; runway extended to "into Q2 2028". All three patients dosed under the modified RP-A501 protocol cleared the safety observation period with no thrombotic microangiopathy or capillary leak syndrome.
- 12 Jun 2026 — Priority review voucher sale closes. The rare paediatric disease voucher awarded with the KRESLADI approval was sold for $180m in gross proceeds, transforming the balance sheet without issuing a share.
- 07 May 2026 — Q1 2026 results. Net loss of $47.6m, or $(0.42) per share; R&D $31.5m; G&A $17.1m; cash and investments down to $144.4m. The definitive agreement to sell the voucher was announced alongside.
- 27 Mar 2026 — FDA approves KRESLADI. Accelerated approval for marnetegragene autotemcel in paediatric patients with severe LAD-I, delivered on the 28 March 2026 goal date. Rocket's first approved product in eight years as a gene-therapy developer.
- 26 Feb 2026 — FY2025 results and Form 10-K. Full-year net loss of $223.1m, or $(2.01) per share, down from $258.7m; R&D $142.0m against $171.2m; cash and investments $188.9m; runway then guided only "into Q2 2027". Headcount disclosed at 202 full-time employees.
- 06 Nov 2025 — Q3 2025 results. Net loss of $50.3m, or $(0.45) per share, with R&D down to $34.1m from $42.3m a year earlier as the restructuring took effect. Rocket also confirmed it had voluntarily withdrawn the US biologics licence application for RP-L102 in Fanconi anaemia on strategic grounds, with no complete response letter involved.
- 13 Oct 2025 — FDA accepts the KRESLADI resubmission. The agency accepted the resubmitted biologics licence application and set a 28 March 2026 goal date. The filing was supported by Phase 1/2 data showing 100% overall survival at twelve months post-infusion with all primary and secondary endpoints met.
- 20 Aug 2025 — FDA lifts the RP-A501 clinical hold. Under three months after imposition, with a recalibrated 3.8x10^13 GC/kg dose, sequential dosing of three patients at four-week intervals and a revised immunomodulatory regimen.
- 24 Jul 2025 — Strategic reorganisation. Roughly 30% of the workforce cut, about 80 people, at a cost of around $3.5m mostly in severance, with twelve-month operating expenses guided down by nearly 25%. The pipeline was reprioritised onto the AAV cardiovascular platform, and the European marketing application for RP-L102 was withdrawn.
- 23 May 2025 — Clinical hold after a patient death. The FDA halted the pivotal Danon disease trial after a treated patient developed capillary leak syndrome with complement activation and later died of an acute systemic infection. This is the event from which the current share price descends.
12. Key Dates
- 10 Sep 2026 — Dr Gaurav Shah takes part in a fireside chat at the 2026 Cantor Global Healthcare Conference, 1:00 PM Eastern, webcast via the investor relations site.
- 15 Sep 2026 — Fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, 9:15 AM Eastern, with management investor meetings alongside.
- Expected 2H 2026 — FDA regulatory-pathway update on RP-A501 covering the dosing of additional Danon patients and completion of the pivotal trial.
- Expected 2H 2026 — Investor webinar giving a comprehensive Danon disease programme update, confirmed as on track in the Q2 2026 release.
- Expected 2H 2026 — FDA update on the planned pivotal study design for RP-A601 in PKP2-ACM, and first patient dosing in the RP-A701 BAG3-DCM Phase 1.
- Expected Nov 2026 — Q3 2026 results. No date has been announced; Q3 2025 was reported on 6 November 2025.
- Expected Q4 2026 — KRESLADI commercial availability and the start of patient onboarding through qualified treatment centres.
There is no outstanding PDUFA date for any Rocket programme following the March 2026 KRESLADI approval. Scheduled macro events that move healthcare and small-cap biotech more broadly are listed on the ChartsView Economic Calendar, and readers can discuss this report in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.